和鉑醫藥(02142.HK)達成抗體藥物偶聯物合作項目
和鉑醫藥-B(02142.HK)公布,公司已與LegoChem Biosciences及映恩生物達成開展抗體藥物偶聯物(ADC)的合作項目,作為公司ADC開發及合作戰略的一環。
今年,公司與映恩生物訂立合作協議,公司將向映恩生物授出其針對特定腫瘤之單克隆抗體的獨家權,以基於映恩生物的免疫毒素抗體偶聯物平台開發全球首創的ADC。同時,與LegoChem Biosciences訂立特許權協議,合作可就ADC開發可供治療的應用。根據協議,公司將收取預付款、里程碑付款及基於銷售的特許使用權費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.